SCHEMBL5296255

SCHEMBL5296255

CCCCC(=O)N[C@H](C)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.70
SMN1; SMN2 Q16637 1/20 0.66
SLC6A5 Q9Y345 1/20 0.66
MEN1 O00255 1/20 0.57
MAPK1 P28482 1/20 0.57
KMT2A Q03164 1/20 0.57
ALDH1A1 P00352 2/20 0.53
MAPT P10636 1/20 0.53
NOD1 Q9Y239 3/20 0.50
PLA2G10 O15496 2/20 0.46
PLA2G2C Q5R387 1/20 0.46
DNM1 Q05193 1/20 0.46
ASAH1 Q13510 1/20 0.44
ACER2 Q5QJU3 1/20 0.44
MME P08473 1/20 0.43
ACE P12821 1/20 0.43
CPA1 P15085 1/20 0.43
ACE2 Q9BYF1 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5966860 1.00 FAAH (0.70) FAAHSMN1; SMN2SLC6A5MEN1MAPK1
SCHEMBL5966857 1.00 FAAH (0.70) FAAHSMN1; SMN2SLC6A5MEN1MAPK1
SCHEMBL9377518 0.94 FAAH (0.78) FAAHSMN1; SMN2SLC6A5MEN1MAPK1
SCHEMBL5936930 0.94 FAAH (0.78) FAAHSMN1; SMN2SLC6A5MEN1MAPK1
SCHEMBL101698 0.94 FAAH (0.78) FAAHSMN1; SMN2SLC6A5MEN1MAPK1
SCHEMBL15649884 0.92 FAAH (0.81) FAAHSMN1; SMN2SLC6A5MEN1MAPK1
SCHEMBL12349998 0.92 FAAH (0.81) FAAHSMN1; SMN2SLC6A5MEN1MAPK1
SCHEMBL342410 0.92 FAAH (0.81) FAAHSMN1; SMN2SLC6A5MEN1MAPK1
SCHEMBL17203936 0.92 FAAH (0.81) FAAHSMN1; SMN2SLC6A5MEN1MAPK1
SCHEMBL12350003 0.92 FAAH (0.81) FAAHSMN1; SMN2SLC6A5MEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0432039-A2 Antipsychotic drug comprising an acylaminoacid NIPPON OILS & FATS CO., LTD. (JP) 1991-06-12 EP claimed
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US disclosed
US-5112863-A N-Acyl Amino Acid Derivative NIPPON OIL & FATS CO., LTD. (JP) 1992-05-12 US disclosed
EP-0432039-A2 Antipsychotic drug comprising an acylaminoacid NIPPON OILS & FATS CO., LTD. (JP) 1991-06-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 FAAH 3814/4885SMN1; SMN2 3894/4885SLC6A5 4119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.